Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue: 2009-2018

Historic Non-Current Deffered Revenue for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Dec 2018 value amounting to $6.3 million.

  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue rose 15.76% to $6.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.3 million, marking a year-over-year increase of 15.76%. This contributed to the annual value of $6.3 million for FY2018, which is 15.76% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Non-Current Deffered Revenue of $6.3 million as of FY2018, which was up 15.76% from $5.4 million recorded in FY2017.
  • Over the past 5 years, Ironwood Pharmaceuticals' Non-Current Deffered Revenue peaked at $10.5 million during FY2014, and registered a low of $557,000 during FY2016.
  • For the 3-year period, Ironwood Pharmaceuticals' Non-Current Deffered Revenue averaged around $4.1 million, with its median value being $5.4 million (2017).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Non-Current Deffered Revenue crashed by 91.29% in 2016, and later soared by 878.28% in 2017.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Non-Current Deffered Revenue stood at $10.5 million in 2014, then slumped by 39.22% to $6.4 million in 2015, then tumbled by 91.29% to $557,000 in 2016, then spiked by 878.28% to $5.4 million in 2017, then climbed by 15.76% to $6.3 million in 2018.